SupraQ development & Placing

Deltex Medical Group PLC
16 February 2007





                            Deltex Medical Group plc

Next generation prototype SupraQTM monitor developed: next phase of development
                            funded by equity placing


16 February 2007 Deltex Medical Group plc ('Deltex Medical' or the 'Company'),
the UK's leading haemodynamic monitoring company, announces the successful
development of a new prototype platform and probe for its non-invasive SupraQ
haemodynamic monitoring system.

This new SupraQ monitor is the first to use pulse-wave rather than continuous
wave Doppler signals. Probes used with this monitor are significantly cheaper to
produce than those used with previous continuous wave SupraQ variants and have
been designed to allow the Company to sell them as a single-patient disposable
probe.

This new platform will give users the clinical utility of the first generation
SupraQ monitor, as reported in work undertaken at both the Medway hospital in
Gillingham and the Royal Free hospital in London, whilst offering significant
improvements in ease of use.

To fund the next stage of development of the new SupraQ, including clinical
trials, the Company today announces the placing with institutional and private
investors of 2,843,163 new ordinary shares of 1p each at 17p per share to raise
£465,290 after expenses. Application will be made for the new shares to be
traded on AIM and it is expected that dealings will commence on 21 February
2007. Following the issue of these new shares the Company has a total of
82,900,288 ordinary shares in issue.

The Company is arranging a demonstration of this new SupraQ at University
College Hospital, London on the afternoon of Tuesday 6 March 2007. For further
details and to reserve a place, please contact Paul Mitchell at
[e-mail].


Deltex Medical's chairman, Nigel Keen, commented:

'This new SupraQ is a major development for the Company. Using pulse rather than
continuous wave Doppler allows us to obtain signals more easily than ever before
as we can look deeper into the aorta, the artery that carries blood from the
heart for distribution to the rest of the body. It also allows us to 'lock' the
signal at the optimum depth for each patient, facilitating inter-operator
repeatability.

'The continuing rise in reported hospital acquired infections means that modern
hospitals are increasingly wary of re-using devices which come into direct
contact with the patient. Using a single-patient disposable probe not only
addresses this problem but also creates the potential for an attractive business
model that includes a comprehensive clinical training and support package for
our customers.'


For further information, please contact:-

Deltex Medical Group plc         01243 774 837
Nigel Keen, Chairman             [e-mail]
Andy Hill, Chief Executive       [e-mail]
Ewan Phillips, Finance Director  [e-mail]

Gavin Anderson & Company         0207 554 1400
Deborah Walter                   [e-mail]
Robert Speed                     [e-mail]

Charles Stanley Securities       020 7149 6457
Philip Davies                    [e-mail]


Notes for Editors

Deltex Medical manufactures and markets the CardioQ monitor, which uses
disposable ultra-sound probes inserted into the oesophagus to determine the
amount of blood being pumped around the body - 'circulating blood volume'.
Reduced circulating blood volume is known as hypovolaemia, which leads to
insufficient oxygen being delivered to the organs. This causes medical
complications including peripheral and major organ failure which can lead to
death. Hypovolaemia, which is akin to severe dehydration, affects virtually
every patient having surgery because of the combined effects of pre-operative
starvation, the impact of the anaesthetic agents and trauma from the surgery
itself. Using fluids and drugs, guided by the CardioQ, to optimise the amount of
circulating blood significantly reduces post-operative complications allowing
patients to make a faster, more complete recovery and return home earlier.

The CardioQ incorporates the Company's proprietary software and a small
diameter, easy-to-use, minimally invasive, disposable oesophageal probe that is
used for transmitting and receiving an ultra-sound signal. By using this
technology, the CardioQ provides clinicians with the ability to haemodynamically
optimise critically ill patients and those undergoing routine moderate to major
surgery through the controlled administration of fluid and drugs. Haemodynamic
optimisation has been scientifically proven to improve the speed and quality of
patient recovery and reduce hospital stay.

There are already over 1,250 CardioQs currently in use in hospitals worldwide
and distribution arrangements are in place in over 30 countries. In addition,
there are currently more than 90 clinical publications on the use of the CardioQ
which have repeatedly:-

   •Validated the results of the Monitor against known standards for
    measuring cardiac output, demonstrating that the technology works

   •Proved that the CardioQ works in a wide range of surgical procedures

   •Demonstrated that the Company's technology provides significant health
    and economic benefits by helping to reduce post-operative complications and
    length of hospital stays by an average of 30 to 40 per cent for a wide range
    of patients.

The SupraQ is an entirely non-invasive device which uses an ultrasound probe
held at the base of the patient's neck to track the flow of blood in the aorta;
it presents the same data as the CardioQ in a similar format and is used for
taking snapshots or monitoring over short periods.




                      This information is provided by RNS
            The company news service from the London Stock Exchange